Petlife Pharmaceuticals, Inc. (OTCPK: PTLF)
Health Care · Pharmaceuticals · US
$—
— today · — 1Y
Petlife Pharmaceuticals, Inc. (OTCPK: PTLF) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $22.21K and employs 1 people.
trading between 0.00 and 0.00.
Tweenvest scores Petlife Pharmaceuticals, Inc. across four factors: quality 8/100. Its strongest factor is quality.
PTLF price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $22.21K
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.04
- Dividend yield
- —
- Beta (5Y)
- 63.38
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 222.12M
- Employees
- 1
- Next earnings
- —
About Petlife Pharmaceuticals, Inc.
Based in Los Angeles, California, Petlife Pharmaceuticals, Inc. is dedicated to the discovery, formulation, commercialization, and ongoing support of both medicinal drugs and nutritional supplements for pets. Their primary focus is on addressing canine and feline cancer and various autoimmune conditions, such as arthritis, within the United States market. The company's leading product is Vitalzul, which functions by obstructing the formation of new blood vessels crucial for the growth of solid tumors. Petlife is also progressing the development of Vitalzul into a potent, prescription-only oral medication, as well as a highly concentrated version for direct intravenous or injectable application to tumors. Additionally, their offerings extend to developing palatable treats suitable for dogs and cats.
- ISIN
- US71639C1036
- Listed since
- May 14, 2008
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.